agosto 2020 – Página 219

miR Scientific elegida finalista en los Premios a la Innovación de Fierce – Ciencias Biológicas, edición 2020

NUEVA YORK, 3 de agosto de 2020 /PRNewswire-HISPANIC PR WIRE/ — miR Scientific LLC, una compañía de biociencias de precisión comprometida en la transformación de tratamientos contra el cáncer, anunció hoy que ha sido elegida finalista en los Fierce Innovation Awards – Life Sciences Edition 2020 (Premios a la Innovación de Fierce, Ciencias Biológicas, edición 2020, un programa de premios de la editorial de Fierce Biotech y Fierce Pharma, evaluados por expertos externos. miR Scientific fue reconocida como Finalista en la categoría de Innovación en Dispositivos Médicos por su revolucionaria prueba de biopsia líquida en orina que puede detectar y calificar, con precisión, el cáncer de próstata de manera no invasiva.

El concurso destaca a las empresas que demuestran innovación en soluciones, tecnologías y servicios en materia de ciencias biológicas con el potencial de lograr grandes impactos.

Sentinel, la prueba para evaluación de próstata de miR, resuelve un problema grave de la vida real que involucra el tratamiento del cáncer de próstata, una enfermedad que representa la mayor cantidad de nuevos casos de cáncer diagnosticados cada año y que es la segunda causa de muerte por cáncer entre hombres en EE. UU.

El estándar actual de atención médica para el diagnóstico de cáncer de próstata se basa en análisis de sangre inexactos del antígeno prostático específico (PSA) con punciones biópsicas con agujas gruesas, muy invasivas, de alto riesgo y costosas, que, en general, son innecesarias. Los actuales estándares son utilizados por menos de la mitad de la población masculina de EE. UU. elegible por edad, lo que agrava todavía más la inequidad en materia de salud y la oportunidad para identificar tipos de cáncer peligrosos anticipadamente para permitir mejores resultados.

La innovadora prueba Sentinel para próstata desarrollada por miR Scientific no es invasiva y puede, con una precisión de más del 90%, detectar el cáncer de próstata y clasificar la categoría de riesgo de tumores malignos con una sola muestra de orina y sin necesidad de biopsias invasivas.

Las solicitudes del programa de premios fueron revisadas por un panel exclusivo de ejecutivos de las principales empresas biotecnológicas y farmacéuticas: Astellas, Accenture, AstraZeneca, Angiocrine Bioscience, Biotech Research Group, NIHR Clinical Research Network, Medidata Solutions y PPD. Todas las solicitudes fueron evaluadas sobre la base de los siguientes criterios: efectividad, innovación técnica, ventaja competitiva, impacto financiero y verdadera innovación. Se puede encontrar la lista completa de los jueces en https://fiercelifesciencesawards.secure-platform.com/a/page/judges

Los ganadores se anunciarán en el Informe de Innovación 2020 que será publicado por Fierce Life Sciences el 14 de septiembre de 2020.

«Nos sentimos honrados por la decisión del comité de premios al seleccionar a miR Scientific como Finalista para los Premios a la Innovación Fierce – Edición de Ciencias Biológicas, edición 2020», dijo Sam Salman, presidente y CEO de miR Scientific. «Sentinel, la prueba de miR para evaluación de próstata, potencia una plataforma integral para el tratamiento de enfermedades que es precisa, no invasiva, independiente y escalable. Como resultado, nuestra plataforma proporciona respuestas claras y evaluables a las preguntas más apremiantes que están en la mente de todo paciente y profesional: ¿Hay presencia de cáncer? En ese caso, ¿cuán grave es y qué se hace luego? Nuestra tecnología puede dar respuestas rápidas y precisas para todas estas preguntas con una simple muestra de orina, lo que debería potenciar un compromiso mucho más amplio con todos los hombres elegibles, incluso las decenas de millones de hombres que actualmente no están recibiendo los excelentes beneficios que representa una detección temprana. Ayudados por nuestro compromiso proactivo con las comunidades de urología y oncología, hemos desarrollado una tecnología innovadora que, confiamos, nos permitirá cambiar para siempre el estándar de atención del cáncer urológico». El señor Salman añadió que «miR Scientific es una organización que busca generar impacto, y creemos que esta tecnología está lista para mejorar las vidas de millones de hombres en todo el mundo. La concienciación y el reconocimiento son los primeros pasos en el largo camino hacia la amplia adopción de tecnologías innovadoras, por lo que estamos agradecidos al comité de premios por habernos elegido como finalistas para el prestigioso Premio a la Innovación Fierce – Edición de Ciencias Biológicas, edición 2020».

Se espera que la prueba Sentinel de miR esté disponible comercialmente en los Estados Unidos a fines de este año y en determinados mercados en Europa y Asia a partir del año 2021.

Acerca de miR Scientific: miR Scientific, LLC es una compañía de biociencias de precisión que se ha comprometido a transformar el tratamiento del cáncer a nivel global. La Compañía ha desarrollado una plataforma propietaria, no invasiva para el efectivo tratamiento del cáncer urológico. La plataforma trabaja con la prueba Sentinel de miR para la evaluación de próstata, una prueba de biopsia líquida en orina que puede detectar, clasificar y monitorear, con precisión, el cáncer de próstata basado en el análisis de ARN pequeños no codificantes tomados de los exosomas urinarios. miR Scientific es la única compañía que cuenta con los productos y servicios interoperables necesarios para revolucionar los estándares de atención que dan soporte a la oncología urológica. Dichos nuevos estándares son muy necesarios dada la prevalencia debilitante y la carga de morbilidad del cáncer de próstata y vejiga en todo el mundo.

Logo – https://mma.prnewswire.com/media/1222688/miR_Logo_color.jpg

FUENTE miR Scientific, LLC

miR Scientific Named a Finalist in the Fierce Innovation Awards – Life Sciences Edition 2020

NEW YORK, Aug. 3, 2020 /PRNewswire-HISPANIC PR WIRE/ — miR Scientific LLC, a precision biosciences company committed to transforming cancer management announced today that it has been selected as a finalist in the Fierce Innovation Awards – Life Sciences Edition 2020, a peer-reviewed awards program from the publisher of Fierce Biotech and Fierce Pharma. miR Scientific was recognized as a Finalist in the category of Medical Device Innovation for its revolutionary liquid biopsy urine test that can accurately detect and grade prostate cancer non-invasively.

The competition highlights companies that demonstrate innovative life sciences solutions, technologies, and services that have the potential to make the greatest impact.

The miR Sentinel Prostate Test solves an acute real-world problem involving the disease management of prostate cancer, a screened disease that represents the highest number of new cancer cases diagnosed annually and is the second leading cause of cancer deaths among men in the US.

The current standard of care for the diagnosis of prostate cancer relies on inaccurate PSA blood tests to trigger very invasive, high risk and costly core needle biopsies, which for the most part are unnecessary. Current standards are utilized by less than half of the age-eligible male population in the US, further compounding health inequity and the opportunity to identify dangerous cancers earlier to allow for better outcomes.

The innovative Sentinel Prostate Test developed by miR Scientific is non-invasive and can, with over 90% accuracy, detect prostate cancer as well as classify the risk category of malignancies based on a single urine specimen and without the need for invasive biopsies.

The awards program’s applications were reviewed by an exclusive panel of executives from major biotech and pharma companies including Astellas, Accenture, AstraZeneca, Angiocrine Bioscience, Biotech Research Group, NIHR Clinical Research Network, Medidata Solutions and PPD. All applications were evaluated based on the following criteria: effectiveness, technical innovation, competitive advantage, financial impact, and true innovation. A full list of judges can be found at https://fiercelifesciencesawards.secure-platform.com/a/page/judges

Winners will be announced in the 2020 Innovation Report set to publish by Fierce Life Sciences on September 14, 2020.

«We are honored by the decision of the award committee to select miR Scientific as a Finalist for the Fierce Innovation Awards – Life Sciences Edition 2020» said Sam Salman, Chairman and CEO of miR Scientific. «Our miR Sentinel Prostate Test powers a comprehensive disease management platform that is accurate, non-invasive, standalone and scalable. As a result, our platform provides clear and actionable answers to the most pressing questions that are on every patient and provider’s mind: Is cancer present and if so, how severe is it and what is next. Our technology can achieve quick and accurate answers to all of these questions from a single urine specimen, which should empower far broader engagement with all eligible men, including tens of millions of men who are not currently receiving the potentially life-saving benefits of early detection. Aided by our proactive engagement with the urology and oncology communities, we have developed a game-changing technology that we are confident will forever change the standard of care for urological cancers.» Mr. Salman added that «miR Scientific is an impact minded organization and we believe this technology is poised to improve the lives of millions of men worldwide. Awareness and recognition are the first steps in the long road to broad adoption of innovative technologies, so we are thankful to the award committee for naming us a finalist for the prestigious Fierce Innovation Award – Life Sciences Edition 2020.»

The miR Sentinel Test is expected to be commercially available in the United States later this year and in select markets in Europe and Asia beginning in 2021.

About miR Scientific: miR Scientific, LLC is a precision bioscience company that is committed to transforming cancer management globally. The Company has developed a proprietary, non-invasive platform for the effective disease management of urological cancers. The platform is powered by the miR Sentinel Prostate test, a liquid biopsy urine test that can accurately detect, classify, and monitor prostate cancer based on the interrogation of small-non-coding RNAs extracted from urinary exosomes. miR Scientific is the only company with the interoperable products and services necessary to revolutionize the standards of care supporting urologic oncology. Such new standards are much needed given the debilitating prevalence and disease burden of prostate and bladder cancers globally.

Logo – https://mma.prnewswire.com/media/1222688/miR_Logo_color.jpg

SOURCE miR Scientific, LLC

Color Star Technology Announces Launching of its Official Website

NEW YORK, Aug. 3, 2020 /PRNewswire/ — Color Star Technology Co., Ltd. (Nasdaq CM: HHT) (the «Company», «we» or «HHT»), a company engaged in the business of providing innovative education services, is pleased to announce that its official website has been successfully launched today.

The official website is: www.colorstarinternational.com. With the new website, investors will be able to find the most up-to-date…

The official website is: www.colorstarinternational.com. With the new website, investors will be able to find the most up-to-date information about the Company. At the same time, the «Fearless, Color World» superstar online concert held on September 9 will also be broadcasted on the website. In the future, investors and customers can browse the Company’s news and future development plans on its website. They can also leave a message or question for the Company to respond to. The website will also be synchronized with mobile application

Biao Lu, CEO of Color Star Technology, said: «Since the Company launched the new business of online education, we truly appreciate the attention we have received so far. Although affected by the global pandemic, our technical team is still working hard to accelerate the progress of software development and website construction. We believe our website will help communicate with our users and we will work together to build a better online education platform with celebrities. We hope to use our website as a starting point to reach many more followers throughout the world.»

About Color Star Technology Co., Ltd.

Color Star Technology Co, Ltd. (Nasdaq: HHT) offers online and offline innovative education services for the music and entertainment industries globally. Its business operations are conducted through its wholly-owned subsidiaries Color China Entertainment Ltd. and CACM Group NY, Inc. The Company’s online education is provided through its Color World music and entertainment education platform. The Company also offers after-school entertainment tutoring in New York via its joint venture entity Baytao LLC.

Forward-Looking Statements

Certain statements made herein are «forward-looking statements» within the meaning of the «safe harbor» provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as «anticipate», «believe», «expect», «estimate», «plan», «outlook», and «project» and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include the business plans, objectives, expectations and intentions of the parties following the completion of the acquisition, and HHT’s estimated and future results of operations, business strategies, competitive position, industry environment and potential growth opportunities. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, our actual results may differ materially from our expectations or projections. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: there is uncertainty about the spread of the COVID-19 virus and the impact it will have on HHT’s operations, the demand for the HHT’s products and services, global supply chains and economic activity in general. These and other risks and uncertainties are detailed in the other public filings with the Securities and Exchange Commission (the «SEC») by HHT. Additional information concerning these and other factors that may impact our expectations and projections will be found in our periodic filings with the SEC, including our Annual Report on Form 20-F for the fiscal year ended June 30, 2019. HHT’s SEC filings are available publicly on the SEC’s website at www.sec.gov. HHT disclaims any obligation to update the forward-looking statements, whether as a result of new information, future events or otherwise.

Color Star Technology Co., Ltd.
Contact: Investor Relations
FinancialBuzzIR™
info@FinancialBuzzIR.com
Tele: +1-877-601-1879

View original content:http://www.prnewswire.com/news-releases/color-star-technology-announces-launching-of-its-official-website-301104470.html

SOURCE Color Star Technology Co., Ltd.

Evofem Biosciences’ CEO Saundra Pelletier Named to PharmaVOICE100 – The Most Inspiring People in Life Sciences

SAN DIEGO, Aug. 3, 2020 /PRNewswire/ — Evofem Biosciences, Inc. (NASDAQ: EVFM) is proud to announce that CEO Saundra Pelletier was named to the PharmaVOICE 100 Most Inspiring People, an annual list of the 100 most innovative, influential and inspirational people in the life-sciences industry.

Ms. Pelletier was recognized for her unwavering commitment to advancing the sexual and reproductive health of women and for her leadership role in Evofem’s rapid growth and evolution. During her tenure as CEO, she has led the Company’s transition to the public market, secured U.S. regulatory approval of Phexxi™ (lactic acid, citric acid and potassium bitartrate), the first and only non-hormonal, prescription contraceptive gel, and raised more than $400 million through multiple financing rounds. The Company is also advancing EVO100 into a Phase 3 clinical trial for the prevention of urogenital transmission of chlamydia and gonorrhea in women.

«Saundra is a visionary leader whose compassion captures your attention, who inspires you to be more, and whose intellect changes your worldview,» said Anne Marbarger, Executive Director at Padres Pedal the Cause. «Under Saundra’s leadership, Evofem Biosciences is bringing to market innovative products that will fundamentally change women’s health and drive gender parity during a time in history where it is particularly relevant.»

Ms. Pelletier was diagnosed with late-stage breast cancer in July 2018 and continued running Evofem while undergoing multiple surgeries and intensive chemotherapy. In addition to her roles as CEO and single mother of a 13-year-old son, she is also active in her community through such organizations as Padres Pedal the Cause.

«I am honored to be recognized by PharmaVoice among such an accomplished group of individuals and am grateful to those who nominated me,» said Ms. Pelletier. «As the CEO of a female-forward company committed to improving women’s health, I am thrilled with the breadth of female leaders and diversity of talent reflected on this list. Together, we are innovating and advocating for new therapies, better care and improved outcomes, while also investing in the next generation of trailblazers, entrepreneurs and glass-ceiling breakers.»

PharmaVOICE Magazine released its annual list of the 100 most inspiring people in life sciences on August 1, identifying industry thought leaders and innovators who have made the biggest impact in their fields.

About Phexxi™ (lactic acid, citric acid and potassium bitartrate) Vaginal Gel
Phexxi is a prescription vaginal gel used to prevent pregnancy in females who choose to use an on-demand method of birth control. Phexxi is only effective when used immediately before (or up to one hour before) each act of vaginal sex. It is not effective when used after vaginal sex.

Important Safety Information

What are the possible side effects of Phexxi?
There have been a few cases of urinary bladder infection and kidney infection reported in clinical studies. One of the cases was serious. Avoid Phexxi if you have had repeated urinary tract infections or other urinary tract problems.

The most common side effects were vaginal burning, vaginal itching, vaginal yeast infection, urinary tract infection, vaginal area discomfort, bacterial vaginosis, and vaginal discharge. Women also reported genital discomfort, pain while urinating, and vaginal pain. Some male partners reported genital discomfort.

What else should I know about using Phexxi?
Phexxi does not protect against any sexually transmitted diseases, including HIV. Avoid using Phexxi with a vaginal ring.

Contact your healthcare provider if you are experiencing severe genital irritation or discomfort or urinary tract symptoms. Avoid Phexxi if you or your sexual partner is allergic to lactic acid, citric acid, potassium bitartrate, or any of the ingredients in Phexxi. Stop using Phexxi if you develop an allergic reaction.

Please see full Prescribing Information for Phexxi, including Patient Information.

Please report side effects by contacting Evofem Biosciences® toll-free at 1-833-EVFMBIO or contact

FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

About Evofem Biosciences, Inc.
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company’s first commercial product, Phexxi™ (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription gel approved in the United States for the prevention of pregnancy. The Company is also advancing EVO100 into Phase 3 clinical trials for the prevention of urogenital transmission of both Chlamydia trachomatis infection (chlamydia) and Neisseria gonorrhoeae infection (gonorrhea) in women. For more information, please visit www.evofem.com.

Forward-Looking Statements
This press release includes «forward-looking statements,» within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended; and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to Evofem’s expectations. Various factors could cause actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements, or that could impair the value of Evofem Biosciences’ assets and business are disclosed in Evofem’s SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 12, 2020, its Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 filed with the SEC on May 6, 2020 and its Current Report on Form 8-K filed with the SEC on June 2, 2020. All forward-looking statements are expressly qualified in their entirety by such factors. Evofem does not undertake any duty to update any forward-looking statement except as required by law.

Contact

Media
Cara Miller
Evofem Biosciences
cmiller@evofem.com
O: (858) 550-1900 x272

View original content to download multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-ceo-saundra-pelletier-named-to-pharmavoice100–the-most-inspiring-people-in-life-sciences-301104413.html

SOURCE Evofem Biosciences, Inc.

RAADR, Inc. Announces launch of virtual overview presentation on Bullying and Cyber Bullying for students

PHOENIX, Aug. 3, 2020 /PRNewswire/ — RAADR, Inc. (OTC PINK: RDAR), a technology and software development company that monitors cyber-bullying and social media platforms with artificial intelligence announces it’s launching a virtual course for students on Bullying. Since most schools around the country are starting back with just virtual online classes due to COVID 19. This virtual overview presentation will allow students to get training and education on cyber bullying and physical bullying. RAADR…

BullyRAADR will be releasing it’s anticipated Video Overview Presentation on the topic of Cyberbullying the first semester of this school year 2020. This video will introduce students to three main factors of online harassment: Identification, Cause, and Response. The presentation will briefly inform students on how to properly identify Cyberbullying, have a greater understanding of its root causes, and how to appropriately respond to many types of online harassment.

CEO Jacob DiMartino says «By improving students’ understanding of Cyberbullying and imparting the tools to successfully respond, we are hopeful that we can positively impact their lives. This new overview presentation will really help the teachers as well working with students dealing with day to day issues.»

About RAADR, Inc.:

RAADR, Inc., makers of the artificial intelligent proprietary technology application RAADR©, have developed a web based tool that provides families with peace of mind when it comes to knowing that their children have a layer of safety from bullying and predatory behavior.

By customizing their own unique monitoring and alert settings, parents and guardians can be alerted when their children’s Facebook, Twitter, Instagram and other pertinent social media platforms containing inappropriate language. By utilizing customized keywords chosen by the user that are added to an already existing database, parents and guardians can carry a sense of assuredness that their child is safe from bullying or being subjected to inappropriate behavior.

Because RAADR© constantly monitors social profiles for threatening activity and language without the parent having to read every update or message, it offers peace of mind to the parents, without requiring continuous monitoring by hand. This also offers a layer of privacy for the students since parents don’t need to comb through their posts and read every one.

RAADR© enables parents to maintain a level of trust with their children while knowing that they are safe from bullying. RAADR© gives families the ability to protect their image, correct erroneous postings and safeguard children from online bullying. The Company’s core focus is building and acquiring apps and other products, services and companies to build a nationwide network of related businesses that are positioned to serve the mobile app development needs of small businesses and individuals.

Contact:
Jacob Dimartino
602-501-3836
jacob.d@raadr.com

View original content:http://www.prnewswire.com/news-releases/raadr-inc-announces-launch-of-virtual-overview-presentation-on-bullying-and-cyber-bullying-for-students-301104505.html

SOURCE RAADR, Inc.

miR Scientific Named a Finalist in the Fierce Innovation Awards – Life Sciences Edition 2020

NEW YORK, Aug. 3, 2020 /PRNewswire/ — miR Scientific LLC, a precision biosciences company committed to transforming cancer management announced today that it has been selected as a finalist in the

NEW YORK, Aug. 3, 2020 /PRNewswire/ — miR Scientific LLC, a precision biosciences company committed to transforming cancer management announced today that it has been selected as a finalist in the Fierce Innovation Awards – Life Sciences Edition 2020, a peer-reviewed awards program from the publisher of Fierce Biotech and Fierce Pharma. miR Scientific was recognized as a Finalist in the category of Medical Device Innovation for its revolutionary liquid biopsy urine test that can accurately detect and grade prostate cancer non-invasively.

The competition highlights companies that demonstrate innovative life sciences solutions, technologies, and services that have the potential to make the greatest impact.

Winners will be announced in the 2020 Innovation Report set to publish by Fierce Life Sciences on September 14, 2020.

The miR Sentinel Test is expected to be commercially available in the United States later this year and in select markets in Europe and Asia beginning in 2021.

View original content to download multimedia:http://www.prnewswire.com/news-releases/mir-scientific-named-a-finalist-in-the-fierce-innovation-awards–life-sciences-edition-2020-301104258.html

SOURCE miR Scientific, LLC

Attorney James R. Snell, Jr. Recognized as a 2020 Legal Elite

LEXINGTON, S.C., Aug. 3, 2020 /PRNewswire-PRWeb/ — Attorney James R. Snell, Jr., was recently named as a «2020 Legal Elite» by Columbia Business Monthly, Greenville Business Monthly, and Charleston Business Monthly magazine. This designation was made after peer voting from other South Carolina attorneys. A feature recognizing this «2020 Legal Elite» designation will be in the magazine’s upcoming August issue.

When presented with…

When presented with this award, Snell said, «It is an honor to be recognized by my peers for this award. But this really represents the strong work of everyone in my office. Without my dedicated and experienced team members, this would not be possible.»

Snell’s practice is focused on criminal defense and personal injury litigation. He recently finished construction of a new office building prominently located on the corner of East Main Street and Harmon Street in downtown Lexington. He has been previously recognized by Super Lawyers, Avvo, Lexington Life Magazine, Columbia Living Magazine, and the National Trial Lawyers Association. He is the past-president of the Lexington County Bar Association, and currently serves as the 11th Circuit Chair for the South Carolina Fee Dispute Committee.

He has a B.S. degree from Limestone College, an A.L.M. degree from Harvard University, and a J.D. from the University of South Carolina. He maintains memberships in the National Trial Lawyers Association, National Criminal Defense Lawyers Association, South Carolina Association of Criminal Defense Lawyers, and the National College for DUI Defense.

The Law Office of James R. Snell, Jr., LLC was founded in November, 2004. Since that time they have represented numerous individuals throughout South Carolina in a variety of criminal and civil legal matters. Their main office is located in downtown Lexington, South Carolina. They also operate a second location in nearby Columbia. You may contact them at (803) 359-3301 or at http://www.SnellLaw.com.

SOURCE Attorney James R. Snell, Jr.

miR Scientific elegida finalista en los Premios a la Innovación de Fierce – Ciencias Biológicas, edición 2020

El concurso destaca a las empresas que demuestran innovación en soluciones, tecnologías y servicios en materia de ciencias biológicas con el potencial de lograr grandes impactos.

Los ganadores se anunciarán en el Informe de Innovación 2020 que será publicado por Fierce Life Sciences el 14 de septiembre de 2020.

Se espera que la prueba Sentinel de miR esté disponible comercialmente en los Estados Unidos a fines de este año y en determinados mercados en Europa y Asia a partir del año 2021.

Logo – https://mma.prnewswire.com/media/1222688/miR_Logo_color.jpg

FUENTE miR Scientific, LLC

miR Scientific Named a Finalist in the Fierce Innovation Awards – Life Sciences Edition 2020

The competition highlights companies that demonstrate innovative life sciences solutions, technologies, and services that have the potential to make the greatest impact.

Winners will be announced in the 2020 Innovation Report set to publish by Fierce Life Sciences on September 14, 2020.

The miR Sentinel Test is expected to be commercially available in the United States later this year and in select markets in Europe and Asia beginning in 2021.

Logo – https://mma.prnewswire.com/media/1222688/miR_Logo_color.jpg

SOURCE miR Scientific, LLC

miR Scientific elegida finalista en los Premios a la Innovación de Fierce – Ciencias Biológicas, edición 2020

El concurso destaca a las empresas que demuestran innovación en soluciones, tecnologías y servicios en materia de ciencias biológicas con el potencial de lograr grandes impactos.

Los ganadores se anunciarán en el Informe de Innovación 2020 que será publicado por Fierce Life Sciences el 14 de septiembre de 2020.

Se espera que la prueba Sentinel de miR esté disponible comercialmente en los Estados Unidos a fines de este año y en determinados mercados en Europa y Asia a partir del año 2021.

Logo – https://mma.prnewswire.com/media/1222688/miR_Logo_color.jpg

FUENTE miR Scientific, LLC